GUIDELINE-DIRECTED MEDICAL THERAPIES FOR DIABETIC KIDNEY DISEASE AMONG THAI PEOPLE WITH TYPE 2 DIABETES: A REAL-WORLD DATA BASED ON THEPTARIN DIABETES STAGING

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

Presented the abstract " "
(Abstract co-author(s): )

Back

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos

E-Poster

https://storage.unitedwebnetwork.com/files/1099/2b61d4d8759c720d97956b0fa9a4687b.pdf

Abstract Title *

GUIDELINE-DIRECTED MEDICAL THERAPIES FOR DIABETIC KIDNEY DISEASE AMONG THAI PEOPLE WITH TYPE 2 DIABETES: A REAL-WORLD DATA BASED ON THEPTARIN DIABETES STAGING

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

The title will not be accepted if it exceeds 25 words.
Type in CAPITAL LETTERS.
Lowercase may be used for abbreviations only, for example, mRNA.

Co-author 1

Peachaphol Chongvoranond peachapl@hotmail.com Vimut-Theptarin Hospital THEPTARIN Diabetes, Thyroid and Endocrine center Bangkok Thailand *

Co-author 2

Waralee Chatchomchaun waralee.md@gmail.com Vimut-Theptarin Hospital THEPTARIN Diabetes, Thyroid and Endocrine center Bangkok Thailand -

Co-author 3

Ekgaluck Wanothayaroj ekgaluck@yahoo.com Vimut-Theptarin Hospital THEPTARIN Diabetes, Thyroid and Endocrine center Bangkok Thailand -

Co-author 4

Siriwan Butadej siriwanbutadej@gmail.com Vimut-Theptarin Hospital THEPTARIN Diabetes, Thyroid and Endocrine center Bangkok Thailand -

Co-author 5

Soontaree Nakasatien soontareenaka@gmail.com Vimut-Theptarin Hospital THEPTARIN Diabetes, Thyroid and Endocrine center Bangkok Thailand -

Co-author 6

Thep Himathongkam thepjudy@gmail.com Vimut-Theptarin Hospital THEPTARIN Diabetes, Thyroid and Endocrine center Bangkok Thailand -

Co-author 7

Yotsapon Thewjitcharoen kamijoa@hotmail.com Vimut-Theptarin Hospital THEPTARIN Diabetes, Thyroid and Endocrine center Bangkok Thailand -

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Introduction

The “pillar approach” has been recently proposed to holistically address diabetic kidney disease (DKD). Theptarin Diabetes Staging (TDS) system was a staging for type 2 diabetes (T2D) to prevent or delay the progression to advanced stages.

Methods

A retrospective study of all medical records of T2D patients with TDS stage 4Ka (moderately increased persistent albuminuria), Stage 4Kb (severely increased persistent albuminuria), and stage 5Ka (eGFR < 45 mL/min/1.73m2) were evaluated. The rate of RASi, SGLT2i, GLP-1 RA, and finerenone together with metabolic attainment targets were evaluated prospectively from year 2021 to 2025.

Results

A total of 206 medical records were reviewed (mean age 64.1±10.3 years, A1C 7.3±1.2%, mean eGFR 71.6±24.5 mL/min/1.73 m2). In 2021, the rate of RASi was 78.2%, SGLT2i in 51.5%, GLP-1 RA in 13.6% of all patients. At 4 years later, the rate of GDMT were improved as follows: RASi 79.7%, %, SGLT2i 59.3%, GLP-1 RA 19.8%, finerenone 2.8%. However, only 1.1% of all patients in 2025 received all 4 GDMT items. More stabilized or improved TDS patients were found in patients who received GDMT ≥ 3 classes from all 4 medication classes when compared with patients who received GDMT < 3 classes (96.2% vs. 78.8%, P-value = 0.036).

Conclusion

The real-world implementation of GDMT among DKD patients were still inadequate and more efforts are required to improve GDMT uptake. Regularly reviews and feedbacks are warranted to improve treatment target attainments and outcomes.

Kewords